Journal article
Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants
Lex W Doyle, Richard A Ehrenkranz, Henry L Halliday
Cochrane Database of Systematic Reviews | WILEY | Published : 2014
Abstract
BACKGROUND: Many preterm infants who survive go on to develop chronic lung disease. This is probably due to persistent inflammation in the lungs. Corticosteroids have powerful anti-inflammatory effects and have been used to treat established chronic lung disease. However, it is unclear whether any beneficial effects outweigh the adverse effects of these drugs. OBJECTIVES: To determine the relative benefits and adverse effects associated with late (> 7 days) postnatal systemic corticosteroid treatment compared with control (placebo or nothing) in the preterm infant with evolving or established chronic lung disease. SEARCH METHODS: We sought randomised controlled trials (RCTs) of postnatal cor..
View full abstractGrants
Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA
Funding Acknowledgements
Internal sourcesAction Research Grant to study long-term follow-up, UK.Action Research (UK) Grant to study the effects of postnatal steroids, UK.External sourcesNational Health and Medical Research Council, Australia.Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA.Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C.